CompletedPhase 4NCT01042158

A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Johns Hopkins University
Principal Investigator
Paul Hassoun, MD
Johns Hopkins University
Intervention
tadalafil and ambrisentan upfront combination therapy(drug)
Enrollment
25 enrolled
Eligibility
18 years · All sexes
Timeline
20102014

Study locations (1)

Collaborators

National Institutes of Health (NIH) · National Heart, Lung, and Blood Institute (NHLBI) · Eli Lilly and Company · United Therapeutics · The Cleveland Clinic · University of Texas · Stanford University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01042158 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis

← Back to all trials